Isabel Roncero

TL;DR: Analysis of the PET studies revealed that the administration of GLP‐1(7–36) amide significantly reduced cerebral glucose metabolism in hypothalamus and brainstem, and the lower activity observed in these areas after peptide administration may be due to reduction of the glucose transport and/or glucose phosphorylation, which should modulate the glucose sensing process in the GLUT‐2‐ and GK‐containing cells.

TL;DR: The colocalization of GLP‐1 receptors, glucokinase, and GLUT‐2 in the same areas supports the idea that these cells play an important role in glucose sensing in the brain.

TL;DR: Findings show that peripheral (s.c.) administration of both GLP-1 receptor agonists also induces satiety and weight loss in rats, and suggest the potential usefulness of exendin-4 as a therapeutic tool for the treatment of diabetes and/or obesity.

TL;DR: The findings indicate that the glucokinase present in rat brain should facilitate the adaptation of this organ to fluctuations in blood glucose concentrations, and the expression of glucokin enzyme and GLUT‐2 in the same hypothalamic neurons suggests a role in glucose sensing.

TL;DR: The presence of glucokinase and glucokin enzyme regulatory protein in the rat brain would facilitate the adaptation of this organ to fluctuations in blood glucose concentrations, and both proteins may participate in glucose‐sensing and metabolic regulation in the central nervous system.